Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

OMLYCLO

OMALIZUMAB-IGEC

Standard Dose
150MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview OMLYCLO is listed in Drugs@FDA under application 761399 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OMALIZUMAB-IGEC Form and strength INJECTABLE;INJECTION - 150MG/ML Sponsor CELLTRION INC Submission history Latest submission status date: 2025-12-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview OMLYCLO is listed in Drugs@FDA under application 761399 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient OMALIZUMAB-IGEC Form and strength INJECTABLE;INJECTION - 150MG/ML Sponsor CELLTRION INC Submission history Latest submission status date: 2025-12-01 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.